Full Press Release Details
SS Innovations International, Inc. to Present
at the Emerging Growth Conference on Wednesday July 12, 2023
SS Innovations invites individual and institutional
investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference
FORT LAUDERDALE, FL, July 10, 2023 -- SS Innovations
International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic
technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that it has been invited
to present at the Emerging Growth Conference on Wednesday July 12, 2023 at 10:50am ET.
The Emerging Growth Conference is a live, interactive
online event that gives existing shareholders and the investment community the opportunity to interact in real time with Dr. Sudhir Srivastava,
CEO, Chairman and Founder of SS Innovations and a pioneer in robotic cardiothoracic surgery.
Dr. Srivastava will present a corporate overview
introducing the Company's innovative flagship SSI Mantra surgical robotic system that is currently being utilized to perform successfully
in a wide array of surgical specialties including Cardiovascular, Thoracic, Head and Neck, Gynecology, Urology, General Surgery, and very
complex robotic cancer operations.
Please submit your questions in advance to Questions@EmergingGrowth.com
or ask your questions during the event and Dr. Srivastava will respond to as many as possible.
Please register here to ensure you are able to
attend the conference and receive any updates that are released: https://goto.webcasts.com/starthere.jsp?ei=1603282&tp_key=1cd1dcc46a&sti=avra_medical
If attendees are not able to join the event live
on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube
Channel, http://www.YouTube.com/EmergingGrowthConference after the event.
About the Emerging Growth Conference
The Emerging Growth conference is an effective
way for public companies to present and communicate their new products, services and other major announcements to the investment community
from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies
in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and
the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors,
as well as Investment advisors and analysts.
All sessions will be conducted through video webcasts
and will take place in the Eastern time zone.
About SS Innovations International, Inc.
SS Innovations International, Inc. (OTC: SSII)
is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible
to a larger part of the global population. SSII's product range includes its proprietary "SSI Mantra" surgical robotic
system, and "SSI Mudra", its wide range of surgical instruments capable of supporting a variety of surgical procedures including
robotic cardiac surgery. SSII's business operations are headquartered in India and SSII has plans to expand the presence of its
technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII's
website at ssinnovations.com or LinkedIn for updates.
Supporting advanced, affordable, and accessible
robotic surgery, the SSi Mantra Surgical Robotic System provides the capabilities for multi-specialty usage including cardiothoracic,
head and neck, gynecology, urology, general surgery and more. With its modular, 3D vision open-console design and superior ergonomics,
the system engages machine learning models to improve safety and efficiency during procedures. The SSi Mantra system has received Indian
Medical Device regulatory approval (CDSCO) and is clinically validated in India in more than 35 different surgical procedures. The company
expects to seek regulatory approvals from the US Food and Drug Administration (FDA) and CE Mark in Europe 2023 and 2024.
Forward-Looking Statements
This press release may contain statements that
are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.
The words "anticipate," "assume," "believe," "estimate," "expect," "will,"
"intend," "may," "plan," "project," "should," "could," "seek,"
"designed," "potential," "forecast," "target," "objective," "goal,"
or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future
events or SS Innovations International's future financial performance and involve known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future
results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
For more information: